Background: Evidence suggests that diets inducing postprandial hyperinsulinemia may be associated with increased cancerrelated mortality. The goal of this study was to assess the influence of postdiagnosis dietary insulin load and dietary insulin index on outcomes of stage III colon cancer patients. Methods: We conducted a prospective observational study of 1023 patients with resected stage III colon cancer enrolled in an adjuvant chemotherapy trial who reported dietary intake halfway through and six months after chemotherapy. We evaluated the association of dietary insulin load and dietary insulin index with cancer recurrence and survival using Cox proportional hazards regression adjusted for potential confounders; statistical tests were two-sided. Results: High dietary insulin load had a statistically significant association with worse disease-free survival (DFS), comparing the highest vs lowest quintile (adjusted hazard ratio [HR] ¼ 2.77, 95% confidence interval [CI] ¼ 1.90 to 4.02, P trend < .001). High dietary insulin index was also associated with worse DFS (highest vs lowest quintile, HR ¼ 1.75, 95% CI ¼ 1.22 to 2.51, P trend ¼ .01). The association between higher dietary insulin load and worse DFS differed by body mass index and was strongest among patients with obesity (HR ¼ 3.66, 95% CI ¼ 1.88 to 7.12, P interaction ¼ .04). The influence of dietary insulin load on cancer outcomes did not differ by mutation status of KRAS, BRAF, PIK3CA, TP53, or microsatellite instability. Conclusions: Patients with resected stage III colon cancer who consumed a high-insulinogenic diet were at increased risk of recurrence and mortality. These findings support the importance of dietary management following resection of colon cancer, and future research into underlying mechanisms of action is warranted.
associated with adverse outcomes in patients with stage III colon cancer (10) . Nevertheless, dietary glycemic load accounts for the insulinogenic response to dietary carbohydrates only, without considering the effects of protein-and fat-rich foods, which also stimulate insulin secretion and are known to act synergistically with carbohydrates (9, (11) (12) (13) . The food insulin index (FII) is a novel parameter that quantifies the postprandial plasma insulin demand elicited by several foods, not just carbohydrates (11) . Foods with higher FII evoke a stronger plasma insulin response; for instance, sweetened Greek yogurt has higher FII than bananas (86.3 vs 60.8), even though the carbohydrate content of Greek yogurt is much lower (11.6 grams vs 22.8 grams per 100-gram portion). Examples of foods with high FII include hard candies (FII ¼ 120) and watermelon (FII ¼ 95.3); in contrast, foods like raw almonds and green peppers have very low FII (5.6 and 3.5, respectively). Using the FII and dietary questionnaires, an individual's dietary insulin load and dietary insulin index, two dietary scores that predict the insulinogenic demand of the overall diet, can be calculated. These scores may shed light on the association between the body's insulin response to diet and survival outcomes in colon cancer survivors.
The goal of our study was to evaluate the association of dietary insulin load and dietary insulin index with disease recurrence and survival of patients with resected stage III colon cancer. We also explored whether microsatellite instability (MSI) and mutational status of KRAS, BRAF, PIK3CA, and TP53 modified the association between dietary insulin scores and patient outcomes.
Methods

Study Population
The patient population in this study was drawn from the National Cancer Institute-sponsored Cancer and Leukemia Group B (CALGB) phase III trial for patients with stage III colon cancer (CALGB 89803), comparing adjuvant chemotherapy with weekly 5-fluorouracil and leucovorin vs weekly irinotecan, 5-fluorouracil, and leucovorin (ClinicalTrials.gov Identifier: NCT00003835) (14) . CALGB is now part of the Alliance for Clinical Trials in Oncology. Between April 1999 and May 2001, 1264 patients were enrolled in the trial. Eligibility criteria included complete surgical resection of the primary tumor within 56 days before study enrollment and evidence of regional lymph node metastases without distant metastasis. Patients were also required to have adequate bone marrow, renal, and hepatic function, as well as a baseline Eastern Cooperative Oncology Group performance status of 0-2. All patients signed informed consent, approved by each institution's review board.
A self-administered questionnaire of dietary and lifestyle habits was given to patients halfway through therapy (four months after surgery, questionnaire 1 [Q1]) and six months after completion of adjuvant therapy (14 months after surgery, questionnaire 2 [Q2]). The original trial protocol was amended to add dietary and lifestyle questionnaires after the first 87 patients were enrolled, leaving 1177 patients who were eligible. Figure 1 illustrates the derivation of the final study population of 1023 patients.
Dietary Assessment
Patients completed semiquantitative food frequency questionnaires (FFQ), developed and validated by Willett et al. (15, 16) , that assessed 131 food items, vitamins, and mineral supplements. Participants answered questions regarding the average frequency with which they consumed a specific food portion size over the previous three months. Each question had up to nine possible answers, ranging from "never" to "six or more times per day." We calculated nutrient intakes by multiplying the frequency of consumption of each food by the nutrient content of the specified portions using composition values from Department of Agriculture sources supplemented with additional data (3). All nutrients were energy-adjusted using the residuals method (17) .
Exposure Assessment
Dietary insulin load and dietary insulin index were calculated as a function of the FII of individual foods. We obtained the FII from previously published estimates (11, 18) or from Dr. Jennie Brand-Miller (University of Sydney, Sydney, Australia) and Laura Sampson-Kent (Harvard T. H. Chan School of Public Health, Boston, MA). Approximately 100 food items and 16 cereals were directly analyzed using a testing procedure previously described (11) . Briefly, study subjects consumed a variety of isoenergetic 1000 kJ (240 kcal) foods and underwent blood insulin measurements every 15 minutes over 120 minutes. The FII was calculated by dividing the area under the insulin response curve (AUC) elicited by each test food by the AUC after ingesting 1000 kJ of the reference food (glucose). The FII scores for the remaining items included in the FFQ were recipe-derived, estimated using mathematical algorithms, or assumed to be zero. A complete list of the assessed food items and their FII scores can be obtained at the Harvard T. H. Chan School of Public Health Nutrition Department's file download site (https://regepi.bwh. harvard.edu/health/nutrition/index.html).
The dietary insulin load for each participant was calculated as follows: dietary insulin load ¼ (R[FII Â kilocalories per serving Â servings per day]). Each unit of dietary insulin load evokes an insulin response equivalent to that of 1-kcal of glucose. The dietary insulin index for each participant's overall diet was computed using the following formula: dietary insulin index ¼ ([dietary insulin load Â 100]/total daily energy intake in kilocalories)). Given that dietary insulin load and dietary insulin index were measured at two time points (Q1 and Q2), we calculated a cumulative average for each dietary insulin score, weighted proportionally to the time elapsed between Q1 and Q2, and between Q2 and disease-free survival time, as described previously (3, 10, 19) . We also obtained weighted cumulative averages for additional dietary exposures (eg, "Western" and prudent dietary patterns [3] , cereal fiber and alcohol intake), body mass index (BMI), and physical activity.
Molecular Assessment for Microsatellite Instability and Mutations of KRAS, BRAF, TP53, and PIK3CA
Study End Points
The primary end point was disease-free survival (DFS), defined as time from completion of Q1 to colon cancer recurrence, occurrence of a new primary colon cancer, or death from any cause. Recurrence-free survival (RFS) was defined as time from completion of Q1 to colon cancer recurrence or occurrence of a new primary colon cancer, or death with evidence of recurrence; patients who died without evidence of recurrence were censored at last date of evaluation. Overall survival (OS) was defined as time from completion of Q1 to death from any cause. Follow-up occurred every three to four months for the first four years, then annually for three years, for a total of seven years of follow-up, and included serum carcinoembryonic antigen (CEA), chest x-rays, and computed tomography scans. First disease recurrence required biopsy confirmation.
Statistical Analysis
We first evaluated the correlation between the dietary insulin load and the dietary insulin index (as continuous variables) using the Pearson correlation coefficient. For survival outcomes analyses, the results of the main treatment trial showed no statistically significant differences in DFS or OS between the treatment arms (14) ; therefore, we combined patients from both arms of the trial and conducted statistical analyses based on quintiles of dietary insulin load and dietary insulin index. Survival end points were analyzed using the log-rank test and Kaplan-Meier curves (26) . Multivariable-adjusted survival analyses evaluating the independent associations of the exposures of interest after adjusting for potential confounders were performed using Cox proportional hazards regression, calculating hazard ratios (HRs) and 95% confidence intervals (CIs) (27) . The proportionality of hazards assumption was tested by evaluating a time-dependent variable of the cross-product of the exposure and time, revealing a violation of the assumption for both dietary insulin scores (P < .05 each) (28) . To address this issue, we included a term for the interaction between dietary insulin load or dietary insulin index and time in the Cox models, allowing for estimation of hazard ratios at different time points. Hazard ratios in the main analyses represent the average hazards of recurrence and death across the entire follow-up period; hazard ratios at one and three years after completion of Q1 are also presented.
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64 (31) 74 (36) 77 (38) 66 (32) 66 (32) 67 (33) 71 (35) 78 (38) 64 (31) 67 ( , physical activity (continuous), cereal fiber (continuous), and alcohol intake (continuous). We conducted linear trend tests across quintiles of dietary insulin load and dietary insulin index by assigning each subject the median value for their corresponding quintile and modeling it as a continuous variable (1) . We conducted tests of interactions by strata of potential effect modifiers by entering the cross-product of dietary insulin load (continuous) and the covariate of interest into the multivariable models and tested for statistical significance using the Wald test.
Statistical analyses were performed using SAS software (version 9.4; SAS Institute, Cary, NC). Statistical significance was set at a P value of less than .05; all hypothesis tests were two-sided. Patient registration and clinical data collection were performed by the Alliance Statistics and Data Center. Statistical analyses were based on the study database frozen on November 9, 2009. Data quality was ensured by review of data by the Alliance Statistics and Data Center and by the study chairperson following Alliance policies.
Results
Dietary Insulin Scores and Baseline Patient Characteristics
The distribution of dietary insulin load and dietary insulin index in our study population is presented in Supplementary Figure 1 (available online); the scores were statistically correlated (Pearson correlation coefficient ¼ .98, P < .001). The median dietary insulin load and dietary insulin index in our population (range) were 831.8 (459.7-1162.1) and 43.5 (24.6-59.4), respectively. Baseline characteristics of patients by quintiles of postdiagnosis dietary insulin scores are shown in Table 1 . Patients with higher dietary insulin load and dietary insulin index were more likely to be female and to be less physically active, and to have higher dietary glycemic load, higher cereal fiber and total carbohydrate consumption, and lower alcohol intake.
Dietary Insulin Load, Dietary Insulin Index, and Colon Cancer Recurrence and Mortality
Median follow-up time among patients who were alive at the end of follow-up was 7.3 years. Higher dietary insulin load and dietary insulin index had statistically significant associations with worse DFS, RFS, and OS ( Figure 2 , Table 2 ). Patients with dietary insulin load in the highest quintile had an adjusted hazard ratio for DFS of 2.77 (95% CI ¼ 1.90 to 4.02, P trend < .001), and this association persisted after further adjusting for dietary glycemic load (a list of food items that made a statistically significant contribution to elevated dietary insulin load independent of dietary glycemic load is presented in Supplementary Table 1, available online). We also found that the association of dietary insulin load with patient outcomes was independent of "Western" and prudent dietary patterns. Similarly, patients with dietary insulin index in the highest quintile had worse DFS compared with those in the lowest quintile (HR ¼ 1.75, 95% CI ¼ 1.22 to 2.51, P trend ¼ .01). We obtained similar results in RFS and OS analyses (Table 2) . Supplementary Tables 2 and 3 (available   Table 1 online) show the hazard ratio estimates corresponding to one and three years after completion of Q1. In sensitivity analyses modeling dietary insulin scores as time-dependent variables, the statistically significant associations between higher dietary insulin load and dietary insulin index and worse DFS (P trend < .001 and P trend ¼ .008, respectively) persisted.
Subgroup Analyses
We evaluated the influence of dietary insulin load on disease recurrence and mortality across strata of potential effectmodifying variables. The association between dietary insulin load and DFS was statistically modified by BMI (P interaction ¼ .04), with the magnitude of the association being highest for patients with obesity ( (Tables 3 and 4) .
Discussion
In a population of resected stage III colon cancer patients enrolled in an adjuvant therapy trial, higher postdiagnosis dietary insulin load and dietary insulin index were associated with increased risk of disease recurrence and mortality. The associations persisted after adjusting for dietary glycemic load and dietary glycemic index, suggesting that protein-and fat-rich foods elicit a postprandial insulin response that may influence cancer outcomes beyond dietary carbohydrates. The association of dietary insulin scores with patient outcomes was independent of "Western" and prudent dietary patterns; however, these results must be interpreted cautiously given that several of the same food items are determinants of dietary insulin scores, as well as of the "Western" and prudent patterns (3), raising concerns about collinearity. Although we can hypothesize about the individual foods that contribute to high dietary insulin scores, the dietary insulin scores were designed to predict the insulinogenic effect of the overall diet rather than any particular food in isolation.
The magnitude of the association with disease recurrence and survival was higher for dietary insulin load than it was for dietary insulin index, suggesting that food energy content plays an important role in this association. Moreover, the association was stronger at one year after initial dietary assessment than at three years. This attenuation could be due to several reasons, including an increase in non-cancer-related deaths as time passes from colon cancer diagnosis, different biological factors influencing early vs late disease recurrence, and changes in dietary patterns over time.
The influence of dietary insulin load on outcomes was strongest among patients who were overweight or obese. Obesity is associated with insulin resistance, which is accompanied by compensatory hyperinsulinemia (29, 30) . Overweight and obese patients in our series might have had elevated basal levels of circulating insulin that were further increased by high dietary insulin load, resulting in higher plasma insulin than a lean patient following the same diet. We recently reported similar findings in patients from two large prospective cohorts in the United States diagnosed with all-stage colorectal cancer (CRC) (31) . Consistent with our results, high dietary insulin load and index were associated with high CRC-specific and overall mortality, and the association was more evident among patients who were overweight or obese. Collectively, our results indicate that a diet that strongly stimulates postprandial insulin secretion is associated with worse clinical outcomes, independent of BMI and physical activity. This finding is consistent with our previous study that reported that elevated circulating C-peptide is associated with higher mortality in CRC patients (5) .
Experimental studies have shown that insulin activates mitogenic and antiapoptotic pathways in tumor cells (32, 33) . Activation of the insulin receptor leads to PI3-kinase(PI3K)/Akt pathway signaling, which modulates genes involved in cell cycle regulation and apoptosis (6) ; it also triggers the Ras-MAPK pathway, which involves the activation of Ras-Raf-MEK1/2-ERK1/2 and promotes cell proliferation (6) . Several cancer types-including CRC-express insulin receptors, and their activation can lead to increased cell proliferation, inhibition of apoptosis, and metastasis (32-34). We did not find statistically significant differences in the influence of insulin load on survival based on KRAS, BRAF, PIK3CA, and TP53 mutation status or microsatellite instability, possibly due to lack of statistical power or to mechanisms beyond those captured by these molecular factors.
The present study has several strengths. The FII of the food items assessed by the FFQ has been validated as an adequate representation of the plasma insulin response elicited by those specific foods (9, 11) . Further, the FII has also been shown to predict the postprandial insulin response to realistic mixed meals, which is of great relevance given the synergistic effect of proteins and carbohydrates to stimulate insulin secretion (9) and the importance of overall dietary patterns (3). Our study was conducted in a population derived from a randomized controlled trial with highly annotated clinical and molecular information, which offers several advantages over traditional observational studies: the baseline clinical characteristics are similar across participants; treatment regimens were highly controlled; follow-up was standardized to streamline ascertainment of disease recurrence and cause of death; and molecular data allowed us to explore interactions between dietary insulin scores and tumor genomic status. Dietary and lifestyle factors were assessed during and six months after completion of adjuvant chemotherapy, allowing for evaluation of changes in dietary habits over time. Although diet and physical activity were self-reported, the questionnaire used in this study has been validated in both healthy populations and cancer patients undergoing chemotherapy (16, 35) , as well as in studies of cardiovascular disease (36,37) and overall mortality (38,39). Our study also has some limitations. Participants in randomized treatment trials need to satisfy stringent criteria to enroll and be motivated to be part of the study, which may raise concerns about generalizability. However, CALGB 89803 enrolled patients from both community and academic centers across North America, and we have not observed statistically significant dietary differences between our study population and that of the general population (10) . Second, if patients in our study had similar pre-and postdiagnosis dietary habits, it is plausible that patients with low prediagnosis dietary insulin load and dietary insulin index had biologically different tumors with more indolent behavior. Nevertheless, this is unlikely because we did not observe statistically significant molecular interactions between dietary insulin load and patient survival. Our main outcome analyses modeled dietary insulin scores as fixed time-independent variables obtained by cumulative averaging, introducing potential for bias; however, sensitivity analyses modeling the scores as time-dependent variables did not result in statistically significant changes to our results.
In summary, we show that postdiagnosis dietary insulin load and dietary insulin index adversely influence patient outcomes in resected stage III colon cancer. Our findings strongly suggest that dietary factors play a role in colon cancer recurrence and survival following resection. Future research efforts should be directed toward understanding the underlying mechanisms of action and impact of dietary counseling on patient survival.
